Cargando…

Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction

Despite widespread preclinical success, mesenchymal stromal cell (MSC) therapy has not reached consistent pivotal clinical endpoints in primary indications of autoinflammatory diseases. Numerous studies aim to uncover specific mechanisms of action towards better control of therapy using in vitro imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Matthew, Khong, Danika, Chin, Ling-Yee, Singleton, Amy, Parekkadan, Biju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931547/
https://www.ncbi.nlm.nih.gov/pubmed/29717209
http://dx.doi.org/10.1038/s41598-018-24971-2
_version_ 1783319657476784128
author Li, Matthew
Khong, Danika
Chin, Ling-Yee
Singleton, Amy
Parekkadan, Biju
author_facet Li, Matthew
Khong, Danika
Chin, Ling-Yee
Singleton, Amy
Parekkadan, Biju
author_sort Li, Matthew
collection PubMed
description Despite widespread preclinical success, mesenchymal stromal cell (MSC) therapy has not reached consistent pivotal clinical endpoints in primary indications of autoinflammatory diseases. Numerous studies aim to uncover specific mechanisms of action towards better control of therapy using in vitro immunomodulation assays. However, many of these immunomodulation assays are imperfectly designed to accurately recapitulate microenvironment conditions where MSCs act. To increase our understanding of MSC efficacy, we herein conduct a systems level microenvironment approach to define compartmental features that can influence the delivery of MSCs’ immunomodulatory effect in vitro in a more quantitative manner than ever before. Using this approach, we notably uncover an improved MSC quantification method with predictive cross-study applicability and unveil the key importance of system volume, time exposure to MSCs, and cross-communication between MSC and T cell populations to realize full therapeutic effect. The application of these compartmental analysis can improve our understanding of MSC mechanism(s) of action and further lead to administration methods that deliver MSCs within a compartment for predictable potency.
format Online
Article
Text
id pubmed-5931547
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59315472018-08-29 Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction Li, Matthew Khong, Danika Chin, Ling-Yee Singleton, Amy Parekkadan, Biju Sci Rep Article Despite widespread preclinical success, mesenchymal stromal cell (MSC) therapy has not reached consistent pivotal clinical endpoints in primary indications of autoinflammatory diseases. Numerous studies aim to uncover specific mechanisms of action towards better control of therapy using in vitro immunomodulation assays. However, many of these immunomodulation assays are imperfectly designed to accurately recapitulate microenvironment conditions where MSCs act. To increase our understanding of MSC efficacy, we herein conduct a systems level microenvironment approach to define compartmental features that can influence the delivery of MSCs’ immunomodulatory effect in vitro in a more quantitative manner than ever before. Using this approach, we notably uncover an improved MSC quantification method with predictive cross-study applicability and unveil the key importance of system volume, time exposure to MSCs, and cross-communication between MSC and T cell populations to realize full therapeutic effect. The application of these compartmental analysis can improve our understanding of MSC mechanism(s) of action and further lead to administration methods that deliver MSCs within a compartment for predictable potency. Nature Publishing Group UK 2018-05-01 /pmc/articles/PMC5931547/ /pubmed/29717209 http://dx.doi.org/10.1038/s41598-018-24971-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Li, Matthew
Khong, Danika
Chin, Ling-Yee
Singleton, Amy
Parekkadan, Biju
Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
title Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
title_full Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
title_fullStr Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
title_full_unstemmed Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
title_short Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
title_sort therapeutic delivery specifications identified through compartmental analysis of a mesenchymal stromal cell-immune reaction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931547/
https://www.ncbi.nlm.nih.gov/pubmed/29717209
http://dx.doi.org/10.1038/s41598-018-24971-2
work_keys_str_mv AT limatthew therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction
AT khongdanika therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction
AT chinlingyee therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction
AT singletonamy therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction
AT parekkadanbiju therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction